NCT07202598View on ClinicalTrials.gov

Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 28, 2025

Primary Completion Date

March 31, 2031

Study Completion Date

September 1, 2031

Conditions
Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy Enteritis
Interventions
DRUG

Emapalumab

Emapalumab will be administered via IV infusion once a month. The initial dose of emapalumab is 3 mg/kg followed by a second dose of 3 mg/kg after 3 days. Subsequently, the dose is 3 mg/kg once a month for five additional doses.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH